NCT06028347View on ClinicalTrials.gov

Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

October 13, 2024

Study Completion Date

October 13, 2024

Conditions
Influenza, Human
Interventions
BIOLOGICAL

sa-mRNA vaccine Dose 1

self-amplifying mRNA vaccine

BIOLOGICAL

sa-mRNA vaccine Dose 2

self-amplifying mRNA vaccine

BIOLOGICAL

sa-mRNA vaccine Dose 3

self-amplifying mRNA vaccine

BIOLOGICAL

Placebo

Saline for injection

Trial Locations (2)

3004

Nucleus network Melbourne Clinic, Melbourne

4006

Nucleus Network Brisbane Clinic, Brisbane

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT06028347 - Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter